Registry of Multicenter Brain-Heart Comorbidity in China
NCT ID: NCT05961748
Last Updated: 2023-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100000 participants
OBSERVATIONAL
2012-01-01
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Any of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \[i.e., ACS\], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).
The data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http://10.100.101.65:30080/login).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research on the Relationship Between Cognitive Function Changes and Cerebrovascular Health in Patients With Coronary Heart Disease
NCT05848934
Prognosis of Patients With Compete Left Bundle Branch Block
NCT03096678
Cardiovascular Disease Cohort
NCT05309824
Impact of Persistent Microvascular Obstruction by Cardiac Magnetic Resonance on Prognosis for ST-segment Elevation Myocardial Infarction
NCT06759532
Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy
NCT05450783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-disciplinary assessment
Multi-disciplinary assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \[i.e., ACS\], I46 (cardiac arrest), I48 (Atrial fibrillation/flutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tiantan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaolin Chen, MD
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shuo Wang, MD
Role: STUDY_CHAIR
Beijing Tiantan Hospital
Yong Cao, MD
Role: STUDY_DIRECTOR
Beijing Tiantan Hospital
Dong Xu, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Zening Jin, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Hao Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Shuai Kang, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Yu Chen, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Qingyuan Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Runting Li, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Heze Han, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Wenxiong Song, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Jionghao Xue, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Minghao Liu, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Tiantan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chinese People's Liberation Army (PLA) General Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China
Shenzhen Qianhai Shekou Free Trade Zone Hospital
Shenzhen, Guangdong, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Huashan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Shanxi Provincial People's Hospital
Shanxi, Shanxi, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ming Gong, MD
Role: primary
Hai Gao, MD
Role: backup
Xiaojuan Guo, MD
Role: primary
Hang Zhu, MD
Role: primary
Wei Ma, MD
Role: primary
Xinggang Wang, MD
Role: backup
Yingqi Xing, MD
Role: primary
Dezhi Kang, MD
Role: primary
Sifang Chen, MD
Role: primary
Zhiwei Wang, MD
Role: primary
Huaizhang Shi, MD
Role: primary
Dongming Yan, MD
Role: primary
Guosheng Zhou, MD
Role: backup
Bin Xu, MD
Role: primary
Feng Xu, MD
Role: backup
Shaohua Ren, MD
Role: primary
Jun Pu, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY2022-221-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.